Castle Biosciences (CSTL) Invested Capital (2018 - 2026)

Castle Biosciences has disclosed Invested Capital across 9 years of filings, most recently posting $471.5 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $471.5 million, up 4.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $471.5 million (up 4.7% YoY), and the FY2025 annual result was $480.9 million, up 3.24% from the prior year.
• Invested Capital came in at $471.5 million for Q1 2026 at Castle Biosciences, down from $480.9 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $480.9 million in Q4 2025 to a low of $378.8 million in Q2 2023.
• The 5-year median for Invested Capital is $421.7 million (2022), against an average of $429.4 million.
• Across the five-year window, Invested Capital retreated 10.17% in 2023 and grew 19.06% in 2024, its largest moves.
• Castle Biosciences' Invested Capital stood at $399.2 million in 2022, then slipped by 1.97% to $391.3 million in 2023, then advanced by 19.06% to $465.9 million in 2024, then climbed by 3.24% to $480.9 million in 2025, then dropped by 1.96% to $471.5 million in 2026.
• The last three Invested Capital figures came in at $471.5 million (Q1 2026), $480.9 million (Q4 2025), and $477.1 million (Q3 2025), per Business Quant data.